Brokers Issue Forecasts for Gain Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:GANX)
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Gain Therapeutics in a note issued to investors on Monday, April 1st. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.04) EPS and FY2025 earnings at ($0.94) EPS.
Separately, Chardan Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a report on Wednesday, March 27th.
Check Out Our Latest Stock Report on Gain Therapeutics
Gain Therapeutics Stock Performance
NASDAQ:GANX opened at $3.99 on Wednesday. Gain Therapeutics has a twelve month low of $2.00 and a twelve month high of $6.19. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $64.72 million, a price-to-earnings ratio of -2.33 and a beta of 0.43. The firm’s fifty day simple moving average is $4.34 and its 200 day simple moving average is $3.45.
Institutional Investors Weigh In On Gain Therapeutics
Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its position in shares of Gain Therapeutics by 947.6% during the 3rd quarter. Royal Bank of Canada now owns 210,000 shares of the company’s stock valued at $689,000 after buying an additional 189,954 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Gain Therapeutics by 47.3% during the 2nd quarter. Geode Capital Management LLC now owns 138,721 shares of the company’s stock valued at $621,000 after buying an additional 44,514 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Gain Therapeutics during the 2nd quarter valued at about $119,000. Northern Trust Corp grew its position in shares of Gain Therapeutics by 227.7% during the 4th quarter. Northern Trust Corp now owns 43,513 shares of the company’s stock valued at $142,000 after buying an additional 30,236 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Gain Therapeutics by 25.8% during the 4th quarter. Vanguard Group Inc. now owns 88,385 shares of the company’s stock valued at $289,000 after buying an additional 18,105 shares during the last quarter. Institutional investors and hedge funds own 11.97% of the company’s stock.
Insiders Place Their Bets
In related news, Director Jeffrey Scott Riley bought 30,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were acquired at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now owns 30,000 shares in the company, valued at approximately $115,800. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 11.00% of the stock is currently owned by company insiders.
About Gain Therapeutics
Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson’s disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Featured Articles
Receive News & Ratings for Gain Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gain Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
